

## 5-Minute Journal Club: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays in the Treatment of Cancer — Issue 2, Colorectal Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following outcomes best represents results of the Phase III CALGB/SWOG-80702 trial evaluating the addition of celecoxib to standard adjuvant therapy for patients with Stage III colon cancer?**
  - No significant disease-free survival (DFS) improvement among patients with and without detectable circulating tumor DNA (ctDNA)
  - Significant DFS improvement among patients with detectable ctDNA**
  - Significant DFS improvement among patients with and without detectable ctDNA
- 2. Which of the following statements best characterizes outcomes from the ctDNA-negative cohort of the DYNAMIC-III study evaluating ctDNA-guided management of adjuvant chemotherapy versus standard management for resected Stage III colon cancer?**
  - ctDNA-guided de-escalation demonstrated superior recurrence-free survival (RFS) in comparison to standard management
  - ctDNA-guided de-escalation demonstrated noninferior RFS in comparison to standard management
  - ctDNA-guided de-escalation demonstrated inferior RFS in comparison to standard management**
- 3. Which of the following populations derived a sustained survival benefit from neoadjuvant immunotherapy in a study evaluating ctDNA monitoring for patients with mismatch repair-deficient/microsatellite instability-high solid tumors?**
  - Patients with positive ctDNA results after immunotherapy
  - Patients with negative ctDNA results after immunotherapy**
  - All patients, regardless of ctDNA status
  - No patients, regardless of ctDNA status
- 4. Which of the following efficacy outcomes was reported for the overall population in the randomized, double-blind Phase III ALTAIR study comparing trifluridine/tipiracil (FTD/TPI) to placebo for patients with molecular residual disease (MRD) after curative resection of CRC?**
  - Inferior DFS with FTD/TPI
  - No significant improvement in DFS with FTD/TPI**
  - A statistically significant improvement in DFS with FTD/TPI
- 5. In a clinical validation study of a methylation-based, tissue-free CRC test for detection of MRD through ctDNA, in which of the following patient populations were survival outcomes significantly worse?**
  - Patients with positive ctDNA results**
  - Patients with negative ctDNA results
  - Patients had similar outcomes regardless of ctDNA status